November 18, 2025

Study Finds Personalized Risk Messages Had No Effect in Raising Colorectal Cancer Screening Participation

A randomized controlled trial to determine the rate of colorectal screening uptake after informing patients due for screening and their providers about the patient’s risk for advanced colorectal neopl...

The ASCO Post

November 04, 2025

Zanzalintinib Plus Atezolizumab vs Regorafenib in Previously Treated Metastatic Colorectal Cancer Without MSI-H or dMMR Tumors

In a phase III trial (STELLAR-303) reported in The Lancet, Hecht et al found that the combination of the multitargeted tyrosine kinase inhibitor zanzalintinib and atezolizumab improved overall surviva...

The ASCO Post

January 01, 0001

Assessment of Pathologic Response in Patients With Locally Advanced Rectal Cancer: Implications of the Park et al. Study

A landmark study reveals the critical role of neoadjuvant chemoradiotherapy in locally advanced rectal cancer treatment, underscoring the importance of treatment response evaluation for better patient outcomes.

JADPRO

January 01, 0001

Ziv-Aflibercept Use in Metastatic Colorectal Cancer

Colorectal cancer remains a leading global health challenge, with advancements in targeted therapies like ziv-aflibercept offering new hope alongside traditional treatments.

JADPRO

January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

December 04, 2023

Consuming Navy Beans May Improve Gut Health, Regulate Immune and Inflammatory Processes in Colorectal Cancer Survivors

Researchers investigated whether the regular consumption of navy beans could help improve the gut microbiome of colorectal cancer survivors.

The ASCO Post

November 13, 2023

FDA Approves Fruquintinib for Refractory Metastatic Colorectal Cancer

On November 8, the FDA approved an anti-VEGF tyrosine kinase inhibitor for adult patients with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based che...

The ASCO Post

June 23, 2023

Expert Point of View: Lisa Newman, MD, MPH, FACS, FASCO

Dr. Lisa Newman emphasizes the critical relevance of including diverse populations in clinical genomic profiling for colorectal cancer, shedding light on potential missed opportunities in homogeneous population studies.

The ASCO Post

April 30, 2025

AACR 2025: Topical BRAF Inhibitor Under Study for Managing Acneiform Rash

Compared with a placebo gel, an investigational topical BRAF inhibitor (LUT014) was found to improve the symptoms of acneiform rash in patients with colorectal cancer. These phase II clinical trial re...

The ASCO Post